TrialAmerican journal of nephrology2008

5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients.

Giuseppe Cianciolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.